AgeneBio Believes a Switch in Research Strategy Can Make Alzheimer’s Preventable

Michela Gallagher, CEO of AgeneBio, and her staff have given themselves a big challenge – to develop the first and only therapeutic targeting brain network imbalance and potentially the first therapeutic to slow progression to and delay the onset of Alzheimer’s dementia, which is becoming a public health crisis. Gallagher believes the biggest roadblock to finding…

AgeneBio Announces First Patient Enrollment in the Phase 3 Clinical Trial to Evaluate AGB101 to Treat Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease

AGB101 is the first investigational therapeutic that targets the reduction of hippocampal overactivity. The study evaluates both Primary and Secondary Endpoints to measure cognitive and functional efficacy. Secondary imaging endpoints will include measures of neurodegeneration. BALTIMORE, MD (January 17, 2019) – AgeneBio announced today that it has enrolled its first patient in a Phase 3…